EP3833370A1 - Compositions destinées à être utilisées dans le traitement de l'obésité - Google Patents
Compositions destinées à être utilisées dans le traitement de l'obésitéInfo
- Publication number
- EP3833370A1 EP3833370A1 EP19729848.2A EP19729848A EP3833370A1 EP 3833370 A1 EP3833370 A1 EP 3833370A1 EP 19729848 A EP19729848 A EP 19729848A EP 3833370 A1 EP3833370 A1 EP 3833370A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- withaferin
- composition
- plant
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 208000008589 Obesity Diseases 0.000 title claims abstract description 20
- 235000020824 obesity Nutrition 0.000 title claims abstract description 20
- 239000000284 extract Substances 0.000 claims abstract description 69
- YCGBUPXEBUFYFV-UHFFFAOYSA-N withaferin A Natural products CC(C1CC(=C(CO)C(=O)O1)C)C2CCC3C4CC5OC56C(O)C=CC(O)C6(C)C4CCC23C YCGBUPXEBUFYFV-UHFFFAOYSA-N 0.000 claims abstract description 64
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 claims abstract description 60
- 235000020230 cinnamon extract Nutrition 0.000 claims abstract description 24
- 241000196324 Embryophyta Species 0.000 claims description 20
- 239000002775 capsule Substances 0.000 claims description 17
- 240000004482 Withania somnifera Species 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 9
- 235000005911 diet Nutrition 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 235000001978 Withania somnifera Nutrition 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- SASUFNRGCZMRFD-JCUIILOWSA-N withanolide D Chemical compound C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=C[C@H](O)[C@@]54O[C@@H]5C[C@H]3[C@@H]2CC1 SASUFNRGCZMRFD-JCUIILOWSA-N 0.000 claims description 6
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 5
- 235000021512 Cinnamomum verum Nutrition 0.000 claims description 5
- 239000007901 soft capsule Substances 0.000 claims description 5
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 4
- 241000208253 Gymnema sylvestre Species 0.000 claims description 4
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 229940094952 green tea extract Drugs 0.000 claims description 4
- 235000020688 green tea extract Nutrition 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- 235000012754 curcumin Nutrition 0.000 claims description 3
- 229940109262 curcumin Drugs 0.000 claims description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 235000021283 resveratrol Nutrition 0.000 claims description 3
- 229940016667 resveratrol Drugs 0.000 claims description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- TZJALUIVHRYQQB-UHFFFAOYSA-N Icarin Chemical compound C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 2
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- 229940074393 chlorogenic acid Drugs 0.000 claims description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 2
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 claims description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229960001285 quercetin Drugs 0.000 claims description 2
- 235000005875 quercetin Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- PFTAWBLQPZVEMU-UHFFFAOYSA-N catechin Chemical compound OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UHFFFAOYSA-N 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 description 10
- 244000080208 Canella winterana Species 0.000 description 6
- 235000008499 Canella winterana Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000016267 Leptin Human genes 0.000 description 6
- 108010092277 Leptin Proteins 0.000 description 6
- 229940017545 cinnamon bark Drugs 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 229940039781 leptin Drugs 0.000 description 6
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 6
- -1 steroid lactone Chemical class 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 235000021035 energy-restricted diet Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 210000003486 adipose tissue brown Anatomy 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000586313 Withania Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000035559 beat frequency Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229930182877 withaferin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- compositions for use in the treatment of obesity are “Compositions for use in the treatment of obesity”.
- the present invention relates to compositions comprising Withaferin A and a cinnamon extract and the use thereof for the treatment of obesity, and in general for the reduction of fat mass. Also kits of portions, comprising a first composition including Withaferin A and a second composition including a cinnamon extract, belong to the present invention.
- Obesity represents a clinical condition characterized by the increase in fat mass and the development of chronic- degenerative pathologies, such as diabetes, arterial hypertension and some forms of tumours ( Pearson-Stuttard J et al, Lancet Endocrinol Diab 2018) .
- the clinical relevance of obesity is underlined not only by its large prevalence and by its clinical correlations, but even by the lack of an effective medical therapy which could contribute in favouring the change of life styles.
- a minimum percentage of patients is obese for precise genetic causes. On the contrary, for most part of patients, the obesity causes are to be found in the not healthy life styles, and in particular in the unbalance between energy introduced with diet and energy consumption through physical activity. Under physiological conditions, the excessive consumption of food is prevented by a series of endocrinological mechanisms, thereamong the circulating levels of leptin hormone (Pan WW et al, Nat Rev Neurosci 2018) .
- Leptin is a polypeptide hormone produced by the adipose tissue proportionally to its sizes. The increase in the circulating levels of leptin triggers the activation of brain areas leading to the decreased appetite and of the caloric intake per os (Pan WW et al, Nat Rev Neurosci 2018) .
- brown adipose tissue Although the brown adipose tissue is limited in man, the transformation of the white tissue into brown tissue, phenomenon called "browning", was demonstrated after physical stimuli, such as the exposition to cold, or pharmacological stimuli (Thyagarajan B et al, Horm Mol Biol Clin Investig 2017) .
- Obesity is a clinical and social problem, which does not recognize effective therapies, with the exception of the bariatric and metabolic surgery even if compositions are known which help the weight loss, such as for example the International patent application Nr. W02005/ 107779 which describes a composition for the weight loss based upon Garcinia cambogia extract, Gymnema sylvestre extract and green tea extract.
- compositions such as for example those described in the patent application US 2011/0052736) are used even for the muscle recovery.
- the object of the present invention is to provide composition and kit useful for the treatment of obesity and more generally for the reduction of fat mass.
- the present invention is based upon the search for and identification of a new combination of natural active principles which used in association exert a synergic effect in the reduction of the fat mass as confirmed by experiments on some obese subjects.
- the present invention relates to compositions comprising Withaferin A and/or an extract of Whitania somnifera including said molecule and a cinnamon extract.
- the present invention further relates to their use in the prevention and treatment of obesity.
- the association Withaferin A and/or an extract of Whitania somnifera including said molecule and cinnamon extract provides a natural solution to the clinical problem of obesity through the normalization of brain sensitivity to leptin, with consequent decreased appetite and caloric intake, and increase in energy expenditure through the "browning" of adipose tissue.
- the present invention describes a composition
- a composition comprising as main active ingredients the cinnamon extract in association with Withaferin A and/or with an extract of Whitania somnifera including such molecule.
- Withaferin A is the main component of the extract of Withania somnifera (that is, Ashwaganda in the ayurvedic tradition), in particular of the root and/or leaves which are the portions most commonly used for the preparation of extracts from said plant. Chemically, Withaferin A is a steroid lactone with important biological properties. Withaferin A returns the normal sensitivity to leptin in experimental models of obesity induced by the diet, by reducing the body weight and improving the metabolic profile associated to obesity. Withaferin A has the following structure formula and it could be prepared according to the procedures known to the person skilled in the art .
- Withaferin A if provided as molecule, as such could be for example administered with a dosing regimen between 50 and 500 mg/die, preferably 300 mg/die (for example lOOmg x 3 times per day, for example one hour before the main meals), alternatively, if provided as extract of Whitania somnifera plant, the dosage of Withaferin A pro die could be administered with a dosing regimen from 2 to 500 mg/die, from 2 to 200 mg/die, from 2 to 100 mg/die, from 2 to 50 mg/die, from 2 to 20 mg/die, from 2 to 10 mg/die, from 2 to 5 mg/die (for example 1-1.5 mg three times per day) .
- the composition could include Withaferin A as insulated molecule and/or an extract of Withania somnifera including such molecule (for example prepared by means of techniques commonly used in the field such as the aqueous extraction, the hydroalcoholic extraction and the like) , in particular an extract as above defined from root of Whitania somnifera preferably titrated at a certain percentage of Withaferin A.
- an extract of Withania somnifera including such molecule for example prepared by means of techniques commonly used in the field such as the aqueous extraction, the hydroalcoholic extraction and the like
- an extract as above defined from root of Whitania somnifera preferably titrated at a certain percentage of Withaferin A.
- extracts of Whitania somnifera plant can be used, having a content of Withaferin A (and then titrated in Withaferin A) from about 0.2% w/w to 20% w/w.
- an extract of Whitania somnifera plant suitable to implement the present invention can have a content of Withaferin A from about 0.2% w/w to 15% w/w, from 0.2% w/w to 10% w/w or from 0.2% w/w to 5% w/w.
- the extract used in the present invention can be an extract or one or more fractions of extract of Whitania somnifera, such as for example an aqueous extract or a hydroalcoholic extract, optionally lyophilised, with a titre in Withaferin A of about 0.2; 0.3, 0.4; 0.5; 0.6; 0.7; 0.8; 0.9; 1 ; 1.5; 2 ; 2.5; 3 ; 3.5; 4 ; 4.5; 5 ; 5.5; 6 ; 6.5; 7; 7.5; 8; 8.5; 9; 9.5; 10; 10.5; 11; 11.5; 12; 12.5; 13; 13.5; 14; 14.5; 15; 15.5; 16; 16.5; 17; 17.5; 18; 18.5; 19; 19.5; 20% w/w of said extract.
- aqueous extract or a hydroalcoholic extract optionally lyophilised
- the authors of the present invention have also surprisingly found that by using the extract of Whitania somnifera plant instead of the molecule of Withaferin A it is possible to administer much lower dosages of Withaferin A pro die than those required with Withaferin A as such.
- the dosage of Withaferin A pro die can be comprised from 2 to 500 mg/die, from 2 to 200 mg/die, from 2 to 100 mg/die, from 2 to 50 mg/die, from 2 to 20 mg/die, from 2 to 10 mg/die, from 2 to 5 mg/die.
- the person skilled in the art could adapt the amount of extract used in the preparation of the formulations to be administered depending upon the used extract of Whitania somnifera.
- the used amount of extract can be reduced when the used extract of Whitania somnifera has a high titre in Withaferin A in the shown range, whereas the used amount of extract can be increased when the used extract of Whitania somnifera has a low titre in Withaferin A with respect to the shown range (0.2-20% w/w) .
- 3 capsules/die can be administered including 150 mg of extract of Whitania somnifera plant titrated at 1% w/w in Withaferin A which correspond to 1.5 mg of Withaferin A per capsule, being equal to a total of 4.5 mg/die.
- 3 capsules/die can be administered including 10 mg di extract of Whitania somnifera plant titrated at 15% in Withaferin a which correspond to 1.5 mg of Withaferin A equalling to a total of 4.5 mg/die.
- 8 capsules can be administered including 250 mg of extract of Whitania somnifera plant titrated at 0.2% w/w in Withaferin A which correspond to 0.5 mg of Withaferin A per capsule, equalling to a total of 4 mg/die.
- the dosage of 4.5 mg/die of Withaferin A if formulated by using an extract of Whitania somnifera as above exemplified can be adapted even during the period of ingestion of the composition of the invention according to the results obtained in time, by decreasing it to 4; 3.5; 3; 2.5; 2 mg/die of Withaferin A if formulated by using an extract of Whitania somnifera, or increased to 5; 5.5; 6 ; 6.5; 7 ; 7.5; 8 ; 8.5; 9 ; 9.5; 10; 15; 20; 25; 30; 50; 100; 200; 300; 400; 500 mg/die of Withaferin A if formulated by using an extract of Whitania somnifera.
- compositions with different amounts of extract of Whitania somnifera can be implemented so as to allow the administration of more or less high dosages without the treated subject having to ingest an excessive number of unitary doses (for example capsule, opercle, pill, granulate, tablet etc.) per day.
- unitary doses for example capsule, opercle, pill, granulate, tablet etc.
- the composition will include even a cinnamon extract, in particular an extract from the cinnamon bark ( Cinnamomum cassia plant or Cinnamomum Verum plant, also called Cinnamomum Zeylanicum) .
- cinnamon extract induces the "browning" of the subcutaneous adipose tissue of animals with obesity induced by the diet, by producing a significant weight loss.
- the extract could be prepared according to the procedures known in the state of art, for example it could be a dry or powder extract.
- an extract of cinnamon bark will be used, prepared with ethanol extraction, in particular having 70% of water, optionally lyophilised.
- An example of cinnamon extract will include mainly: protocatechuic acid (for example about 17.3 mg/kg), catechin (for example about 302 mg/kg), chlorogenic acid (for example about 25.1 mg/kg), aesculetin (for example about 12.7 mg/kg), quercetin (for example about 180.9 mg/kg) and icarin (for example about 51.1 mg/kg) .
- the cinnamon extract could be administered for example with a dosing regimen from 50 to 2000 mg/die, in particular 1800 mg/die, preferably in 3-6 separate administrations (for example 600mg x 3 times per day, or 300 mg 6 times per day) .
- the composition does not comprise at least two, at least three, at least four, at least five or at least six of the following components: Garcinia cambogia extract, Gymnema sylvestre extract, green tea extract, curcumin, resveratrol and aspartic acid, or derivatives thereof.
- the composition comprises an extract of Withania somnifera plant (preferably from root and leaves) and a cinnamon extract as unique active ingredients for the reduction of the body weight. Therefore, the composition can include other components, such as for example carriers, excipients, stabilizers, preservatives, and the like, but it does not comprise other principles or compounds active in the weight loss or control.
- the composition of the invention comprises cinnamon extract in any herein defined form, Withaferin A and/or extract of the Whitania somnifera plant comprising Withaferin A (preferably from root) in any herein defined form and at least one or more pharmaceutically acceptable substances selected among excipients, stabilizers, preservatives, glidants, fillers, humectants, disintegrants , binders, retardants, absorption accelerators, adsorbents, lubricants and the like.
- composition according to the invention can include cinnamon extract in any herein defined form, Withaferin A and/or extract of the Whitania somnifera plant including Withaferin A (preferably from root) in any herein defined form and one or more pharmaceutically acceptable excipients.
- compositions according to the present invention can be formulated under any form and administration route and associated to any other component, in a variety of ways, preferably they will be formulated for oral use for example as capsules, soft capsules, tablets, pills, gelatines, powders or granules.
- excipients can be selected for example among those normally used in the state of art and include, but they are not limited thereto: a) carriers, such as for example sodium citrate and calcium phosphate, b) fillers such as for example starch, lactose, microcrystalline cellulose, sucrose, glucose, mannitol, triglycerides and colloidal silica, c) humectants, such as for example glycerol, d) disintegrants , such as alginates, calcium carbonate, starches, derivatives of starch, of cellulose and of polyvinylpyrrolidone, silicates and sodium carbonate e) binders such as carboxymethylcellulose, alginates, gelatine, polyvinylpyrrolidone, sucrose, polymeric derivatives of cellulose, starch derivatives f) retarding agents such as paraffin, cellulose polymers, esters of fatty acids g) absorption accelerators, such as quaternary ammonium compounds, h) wetting
- solid dosage such as tablets, capsules, soft capsules, gelatines, pills and granules
- enteric, gastric coatings or coatings of other type known in the state of art can include opacifers and can be of the type to allow the release of the active ingredients only or preferably in a certain tract of the intestine, in case, in a delayed manner.
- Substances which can allow such delayed use include, but they are not limited thereto, polymers and waxes.
- the soft capsules could house the antioxidant substances in liquid forms alone or in solutions, suspensions or emulsions of the active substances in a liquid solvent.
- the soft capsules could be characterized by a casing qualitatively similar to that of the stiff ones but thicker and soft.
- Liquid forms suitable to an oral administration are for example emulsions, solutions, prepared or extemporaneous suspensions, syrups and elixirs.
- Excipients suitable to the formulations according to the present invention in liquid forms for oral use include, but they are not limited thereto, diluents such as water or other solvents, solubilizing agents and emulsifying agents selected from ethyl alcohol, polyalcohols, propyl glycol, glycerol, polyethylenglycol and sorbitan esters. These formulations can even include sweeteners and flavours.
- compositions will be for example a medical device, a food supplement, a nutraceutical , dietetic and nutritional composition, a food product, a beverage, a neutraceutical , a medicament, a medicated food, food for special medical purposes, food, a pharmaceutical composition.
- the compositions will be mainly intended to be used by the human beings, but they could also be used on animals.
- the combination of the above-mentioned active ingredients could be used formulated in one single composition according to the various above-described embodiments or in a kit including the different separate ingredients, for example in single compositions such as capsules, pills tablets for sequential or contemporary administration of the different ingredients.
- compositions could be used/administered/ingested for preventing and/or treating obesity, in particular in female subjects. They could also be used by not obese patients to reduce the fat mass.
- the combination of active ingredients according to the present invention will be administered with a daily dosing regimen according to the above-mentioned amounts.
- compositions for oral use will include for example between 10 and 5000 mg of Cinnamon extract per dosage unit and between 10 and 5000 mg of insulated Withaferin A, or 2-500 mg of Withaferin A if formulated by using an extract of Whitania somnifera per dosage unit, preferably between 50 and 500 mg of Cinnamon extract per dosage unit and between 50 and 500 mg of insulated Withaferin A, or 2-100; 2-50; 2-20; 2-10; 2-5 mg of Withaferin A if formulated by using an extract of Whitania somnifera .
- compositions of the present invention are shown hereinafter.
- composition for oral use in form of capsule Composition for oral use in form of capsule
- composition for oral use in form of pill
- EXAMPLE 3 Composition for oral use in form of pill, capsule, opercle, granulate or tablet
- the invention relates to, the inventors performed a clinical study by following the protocol described hereinafter. The study was performed with consenting and informed patients and the medical protocol was approved by the ethics committee of the University "SAPIENZA" in Rome.
- Age comprised between 25 years old and 75 years old
- the recruitment will exclude the patients having: symptomatic chronic cardiac deficiency (NYHA class III- IV); congenital heart diseases; tacho-brady arrhythmias with poor pharmacological control; neoplasia in progress; acute heart attack or acute coronary syndrome within 3 months preceding the inclusion in the study; acute infections or inflammations in progress; valvulopathy; cognitive deficit or poor compliance to the treatment; concomitant treatment with thyroid hormones or other drugs interfering with metabolism. Pregnant or fertile women, not using adequate contraceptive methods, will be excluded from inclusion.
- the demographic and clinical features will be synthetized by means of descriptive statistics (average, standard deviation, median, interquartile range) in case of continuous variables and by means of absolute frequencies and percentages in case of categoric variables.
- the distribution normality of all variables will be tested by using Kolmogorov-Smirnov test.
- the comparison between percentages will be performed by means of chi-square test or with the exact test of Fisher (if n ⁇ 5) .
- the correlation coefficients of Pearson or Sperman will be used for analysing the dependence between variables.
- the intra-subject weight variation will be evaluated by means of a t-test for paired data.
- the comparison analysis between the two types of intervention will make use of an analysis of the variance for repeated measurements or, if required, not parametric tests.
- the statistical software R (3.3.2) will be used for the statistical analysis.
- the study was performed on a sample of 40 subjects.
- the performed study is a perspective, double-blind study) , cross-over with randomized AB/BA drawing: such mode was selected as at the beginning of a dietary-nutritional programme the adherence is higher and this could constitute a bias.
- the primary end-point of the study is the variation in the body weight with energy restricted diet and use of the association of extract of Withania somnifera and of extract of cinnamon bark with respect to the body weight with energy restricted diet and placebo.
- the systemic effects of the association can also be evaluated through markers of inflammation (that is, CRP, ratio neutrophils on lymphocytes) and of sugar metabolism (that is, glycaemia) and lipidic metabolism (that is, total cholesterol and triglycerides) and/or the effects of the association on the abdominal and gluteal circumference.
- CRP CRP
- sugar metabolism that is, glycaemia
- lipidic metabolism that is, total cholesterol and triglycerides
- the treatment A consists in capsules containing 300 mg of extract of cinnamon bark, 150 mg of extract of the root and the leaves of Withania sominifera plant titrated at about 0.5% in Withaferin A and 10 mg of magnesium stearate, whereas the treatment B in capsules containing an equal dose of starch and cellulose, to be ingested three times per day.
- a diet is meant determining a loss of 20% of the calories usually introduced by the patient.
- a diet is processed determining a loss of 20% of the calories usually introduced by the patient.
- the amount is provided to the patient for 4 weeks of association or placebo (depending upon the results of randomization) .
- the patient is called again for a medical examination wherein a new clinical and nutritional evaluation is performed.
- the patient starts the treatment B or A by using the provided material.
- the patient is examined again and the results are recorded. At this point, the patient exits the study as he/she has completed the protocol, and he/she will continue to be followed by our centre.
- each patient is subjected to a blood withdrawal apt to evaluate the routine indexes (creatinine, azotemia, uricemia, blood count, triglycerides, total cholesterol, HDL, LDL, glycaemia) .
- routine indexes creatinine, azotemia, uricemia, blood count, triglycerides, total cholesterol, HDL, LDL, glycaemia.
- the used cinnamon extract is a dry extract of bark of Cinnamomum Cassia obtained by the extraction ethanol/water such as, for example, the dry extraction of a bark of Cinnamomum Cassia commercialized by FlaNat research.
- the used extract of Withania somnifera is a dry extract of roots and leaves of Withania somnifera plant obtained by extraction in water and which has the following composition: glycosides Witanolides 3 10% w/w, oligosaccharides 3 32% w/w and aglycone of Witanolide (such as Withaferin A) ⁇ 0.5% w/w such as, for example, the dry extract of roots and leaves of Withania somnifera plant commercialized by Natreon (Sensoril®) .
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102018000005336A IT201800005336A1 (it) | 2018-05-14 | 2018-05-14 | Composizioni per uso nel trattamento dell’obesità |
PCT/IB2019/053980 WO2019220335A1 (fr) | 2018-05-14 | 2019-05-14 | Compositions destinées à être utilisées dans le traitement de l'obésité |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3833370A1 true EP3833370A1 (fr) | 2021-06-16 |
Family
ID=63312236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19729848.2A Withdrawn EP3833370A1 (fr) | 2018-05-14 | 2019-05-14 | Compositions destinées à être utilisées dans le traitement de l'obésité |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3833370A1 (fr) |
IT (1) | IT201800005336A1 (fr) |
WO (1) | WO2019220335A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112022842A (zh) * | 2020-09-23 | 2020-12-04 | 中国农业大学 | 原儿茶酸用于制备增加能量代谢和帮助寒冷环境中维持体温的药物中的应用 |
KR20230129831A (ko) * | 2022-03-02 | 2023-09-11 | 주식회사 에이치엘사이언스 | 아쉬아간다 추출물 및 구절초 추출물의 복합물(asc복합물)을 유효성분으로 포함하는 비만의 예방, 개선 또는 치료용 조성물 |
KR102614233B1 (ko) * | 2022-11-25 | 2023-12-19 | (주)엔에스티바이오 | 12-디옥시위타스트라모놀라이드와 그 유도체를 포함하는 체지방 감소용 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9700590B2 (en) * | 2004-03-01 | 2017-07-11 | In Ingredients, Inc. | Methods and materials for reducing or eliminating risk factors associated with syndrome X |
CN101132697A (zh) * | 2004-04-30 | 2008-02-27 | 新Hc配方设计公司 | 用于减轻体重的组合物和减轻体重的方法 |
US20110064720A1 (en) * | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
JP6672157B2 (ja) * | 2013-11-26 | 2020-03-25 | ザ チルドレンズ メディカル センター コーポレーション | 肥満を処置するための化合物およびその使用方法 |
AU2014363403A1 (en) * | 2013-12-12 | 2016-05-05 | Société des Produits Nestlé S.A. | Methods and compositions for increasing energy expenditure using cinnamaldehyde |
-
2018
- 2018-05-14 IT IT102018000005336A patent/IT201800005336A1/it unknown
-
2019
- 2019-05-14 EP EP19729848.2A patent/EP3833370A1/fr not_active Withdrawn
- 2019-05-14 WO PCT/IB2019/053980 patent/WO2019220335A1/fr active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
WO2019220335A1 (fr) | 2019-11-21 |
IT201800005336A1 (it) | 2019-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6541046B2 (en) | Herbal composition and method for controlling body weight and composition | |
CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
US9603866B2 (en) | Anti-fatigue composition, formulation and use thereof | |
EP1763359B1 (fr) | Utilisation de glucosides de pregnane pour le traitement /gestion de l'obesite | |
EP3833370A1 (fr) | Compositions destinées à être utilisées dans le traitement de l'obésité | |
SG191621A1 (en) | Composition comprising 1, 3 /1, 6 beta glucan for reducing weight | |
HUE034393T2 (en) | Increasing the bioavailability of a drug in naltrexone therapy | |
Bager | Assessment report on Zingiber officinale Roscoe, rhizoma | |
KR101511364B1 (ko) | 복합 생약재를 이용한 비만 및 대사증후군의 예방 또는치료용 조성물 | |
WO2016124080A1 (fr) | 20(r)-ginsenoside rg3 destiné à la préparation d'un médicament pour la prévention et/ou le traitement de l'obésité ou ses applications et médicament associé | |
CN105233288A (zh) | 一种治疗或预防肥胖型高血压的药物组合物及其用途 | |
WO2016041826A1 (fr) | Compositions thérapeutiques et nutritionnelles contre les troubles gastro-intestinaux fonctionnels | |
JP2021518852A (ja) | 心血管疾患又は脳血管疾患を治療する漢方薬組成物及びその調製方法並びに使用 | |
CN110292607B (zh) | 治疗高血压病并发左心室肥厚的中药组合物及制备方法 | |
Shiojima et al. | Effect of ellagic acid on body fat and triglyceride reduction in healthy overweight volunteers: A randomized, double-blind, placebo-controlled parallel group study | |
CN105194352B (zh) | 一种改善学习记忆的中药组合物及其制备方法 | |
CN105944104B (zh) | 一种治疗消化道溃疡的药物组合物 | |
CN108175793A (zh) | 一种兽药组合物及其制备方法和应用 | |
US20200246414A1 (en) | Compositions and methods for the treatment of constipation and other ailments of the gastrointestinal system | |
CN108379379A (zh) | 用于痛风急性期的中药组合物 | |
CN105246472B (zh) | 含有鸟氨酸和/或门冬氨酸的组合物及其应用 | |
BR112020005856A2 (pt) | uso de uma composição contendo benzoato para tratar encefalopatia da glicina | |
CN102283832B (zh) | 一种预防或治疗高血压肥胖患者的药物组合物及用途 | |
CN103893512B (zh) | 一种治疗痛风性关节炎的中药组合物 | |
RU2780451C1 (ru) | Композиция на основе лекарственных материалов традиционной китайской медицины для лечения метаболического синдрома, способ ее получения и применение, и фармацевтический препарат на ее основе и его применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210330 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220425 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231201 |